Ventyx Biosciences Proposed Sale to Eli Lilly Under Investigation by Kahn Swick & Foti for Adequacy of Price and Process.

Kahn Swick & Foti, LLC is investigating the proposed sale of Ventyx Biosciences to Eli Lilly and Company, with shareholders set to receive $14.00 in cash per share. The firm is seeking to determine if the consideration is adequate and if the process leading to it undervalues the company. If you believe the transaction undervalues Ventyx, you can contact KSF for more information without obligation or cost.